Continue Reading
Full article on Yahoo Finance
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
Market Intelligence Analysis
AI-Powered
Why This Matters
MediciNova has enrolled 100 patients in the SEANOBI study, a 50% milestone towards the planned 200 patients, evaluating MN-166 (ibudilast) in ALS patients through an expanded-access-program.
Market Impact
Market impact analysis based on bullish sentiment with 85% confidence.
Sentiment
Bullish
AI Confidence
85%
Time Horizon
Short Term
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the end of January 2026, 12 sites in the US are activated and 100 patients have been enrolled in the SEANOBI study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS; NCT 06743776) representing 50% of the planned 200-en
Original article published by
Yahoo Finance
on January 30, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.